ArticleMolecular pharmaceutics2023
Efficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment of Androgenetic Alopecia.
Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Development and validation of a comprehensive in vitro organ model for androgenetic alopecia.BMC biotechnology · 2026Article
- Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia.Pharmaceutical medicine · 2026Review
- Double Knockdown of the Androgen Receptor Target Genes DKK1 and SFRP1 Does Not Potentiate the Hair Growth-Promoting Effect of SFRP1 Silencing in Healthy Human Hair Follicles Ex Vivo.International journal of molecular sciences · 2026Article
- Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis.Scientific reports · 2026Article
- Use of genetics in the prediction of success in male pattern hair loss therapy and mechanistic studies.Frontiers in pharmacology · 2026Review
- Updates in Treatment for Androgenetic Alopecia.Annals of dermatology · 2025Review
- Self-assembling peptide inspired by insulin and type 1 insulin-like growth factor for the treatment of androgenetic alopecia.Bioactive materials · 2025Article
- Meloside A Protects Dermal Papilla Cells from DHT-Induced Damage via Androgen Receptor Modulation.Current issues in molecular biology · 2025Article
- Targeted self-assembled anti-NFκB AuNCs-aptamer nanoplatform for precise theranostics via tailored follicle regeneration.Materials today. Bio · 2025Article
- Recent Advances in Drug Development for Hair Loss.International journal of molecular sciences · 2025Review
- Curcumin-primed milk-derived extracellular vesicles remodel hair follicle microenvironment for the treatment of androgenetic alopecia.Regenerative biomaterials · 2025Article
- Jiawei Erzhiwan Ameliorates Androgenetic Alopecia by Regulating the SIRT1/JNK/p38 MAPK Pathway.Drug design, development and therapy · 2025Article
- Effects of oxytocin receptor agonists on hair growth promotion.Scientific reports · 2024Article
- Improvement of androgenic alopecia by extracellular vesicles secreted from hyaluronic acid-stimulated induced mesenchymal stem cells.Stem cell research & therapy · 2024Article
- Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy.International journal of molecular sciences · 2024Review
- Recent approaches of antibody therapeutics in androgenetic alopecia.Frontiers in pharmacology · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asymmetric small interfering RNAs (asiRNAs) that mediate RNA interference have been investigated for therapeutic use in various tissues, including skin tissue. Androgenetic alopecia (AGA) is caused by a combination of genetic factors, resulting in sensitivity to dihydrotestosterone (DHT), which binds to the androgen receptor (AR) to mediate a series of biomolecular changes leading to hair loss. This study aimed to evaluate the therapeutic potential of a cell-penetrating, AR-targeting asiRNA (cp-asiAR) for AGA treatment, which was designed to silence the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.